Filing Flows › Kestra Medical Technologies (KMTS) › Q3 FY26
Kestra Medical Technologies (KMTS) Q3 FY26 earnings results (third quarter fiscal 2026)
10-Q filed Mar 17, 2026
Kestra Medical Technologies (KMTS) reported revenue of $24.6M for the third quarter fiscal 2026 (Q3 FY26), +63% from a year earlier and +9% from the quarter before. Operating margin was -141.6%, net loss $34.2M (139.2% of revenue).
Kestra Medical Technologies, Q3 FY26: revenue $24.6M (+63% year over year), operating margin -141.6%, net loss $34.2M, operating cash flow −$18.4M. The chart follows the revenue to costs, profit and cash.
| Q3 FY26 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $24.6M | +9% | +63% |
| Operating profit | −$34.8M | — | — |
| Net earnings | −$34.2M | — | — |
| Operating cash flow | −$18.4M | — | — |
What changed
Revenue was $24.6M in Q3 FY26, up 63% year over year and up 9% from the previous quarter.
Gross margin was 52.6%, up 9.2 points from Q3 FY25. Operating costs exceeded revenue by $34.8M, an operating margin of -141.6%. Operating expenses grew 76% against revenue growth of 63%. The fastest-growing cost line was SG&A (+79%). The quarter ended with a net loss of $34.2M, wider than the previous quarter's $32.8M loss.
Operating cash flow was −$18.4M. Non-cash charges added back $2.0M of depreciation and $10.1M of share-based compensation. Working capital and other items added $3.7M. Capital expenditures of $9.8M exceeded it, leaving free cash flow of −$28.2M.
Questions
What was Kestra Medical Technologies' revenue in the third quarter fiscal 2026?
Kestra Medical Technologies (KMTS) reported revenue of $24.6M for the third quarter fiscal 2026 (Q3 FY26), +63% from a year earlier and +9% from the quarter before.
Was Kestra Medical Technologies profitable in the third quarter fiscal 2026?
Operating loss was $34.8M (-141.6% of revenue) and net loss $34.2M.